The 58-Year-Old with Lumbar Stenosis, Diabetes, and a Request for 'the Minimally Invasive Option'
A 58-year-old man with a 2-year history of neurogenic claudication (walks 2 blocks, relieved by sitting) has MRI showing L4-L5 central stenosis with ligamentum flavum hypertrophy and facet arthropathy, without spondylolisthesis. He has type 2 diabetes (HbA1c 9.1%), is on insulin, and has peripheral neuropathy documented on EMG. He has read about 'minimally invasive decompression' and wants the smallest possible operation. He is obese (BMI 36) and has had no prior spine surgery. On exam he has normal strength, no focal motor deficit, and a positive treadmill test reproducing symptoms. He asks whether he can avoid fusion and whether the diabetes matters for his recovery.
1. How do you counsel him on decompression versus fusion, and on the 'minimally invasive' request?
Read the worked answer
This is a textbook case for decompression without fusion. The key anatomic fact is the absence of spondylolisthesis or deformity - instability is what drives the fusion decision, not stenosis severity. Isolated lumbar stenosis without listhesis is well supported by randomized evidence for decompression alone, with fusion adding morbidity without clear benefit and increasing the risk of adjacent-segment disease. 'Minimally invasive' is a technique, not a diagnosis: a tubular or microscopic decompression can achieve adequate neural element release, but the goal is adequate decompression, and an inadequate minimally invasive decompression that leaves residual stenosis is worse than a well-performed open one. I would tell him the appropriate operation is a laminectomy/decompression at L4-L5, which can often be done through a muscle-sparing approach in his BMI, but I would not promise a specific incision size. I would explicitly separate his request ('smallest operation') from his goal ('walk without stopping'), and explain that the right operation is the one that reliably addresses the stenosis.
2. What does his diabetes and neuropathy mean for surgical risk, informed consent, and expected outcome?
Read the worked answer
The HbA1c of 9.1% is the dominant modifiable risk. Poor glycemic control is associated with higher surgical site infection, poorer wound healing, and worse functional outcomes after spine surgery. I would not necessarily cancel surgery, but I would counsel him that optimizing glucose control preoperatively (targeting lower HbA1c, coordinating with his endocrinologist) reduces infection risk, and I would consider it a shared decision about timing. His pre-existing peripheral neuropathy complicates informed consent: some of his leg symptoms may be neuropathic rather than purely claudicant, and decompression will not reverse established neuropathy. I would set expectations that claudication and walking distance should improve, but burning/numbness from neuropathy may persist. I would also flag that his obesity increases wound complication and anesthesia risk. The consent conversation should distinguish 'what surgery fixes' (stenosis-related claudication) from 'what it does not fix' (diabetic neuropathy), and document that he understands the infection risk and the rationale for glycemic optimization.